Recently, three CDK4/6i (palbociclib, abemaciclib, and ribociclib) have received FDA approval to treat estrogen receptor (ER)-positive, Erb-B2 Receptor Tyrosine Kinase 2 (HER2)-negative advanced breast cancer in combination with endocrine therapy6,7. This evidence concerns the gene CDK4 and breast carcinoma.